Colorectal cancer, radiotherapy and gut microbiota
Authors:
- Weiwei XiaoWXWeiwei Xiao
- Yuanhong GaoYGYuanhong Gao
- State Key Laboratory Of Oncology In South ChinaSCState Key Laboratory Of Oncology In South China
Open Access
- 1 January 2019
- journal article
- review article
- Published by Chinese Journal of Cancer Research in Chinese Journal of Cancer Research
- Vol. 31 (1) , 212-222
Abstract
Colorectal cancer is closely related to inflammation and immune response. Radiotherapy, as a major treatment for colorectal cancer, plays a central role in cancer control. Inflammation caused by ionizing radiation can exert either anti- or pro-tumorigenic effects. Additionally, radiotherapy can elicit an anti-tumor response not only in radiation of target lesions but also in radiation of remote lesions. However, the immune mechanism underlying this effect has not been thoroughly elucidated yet. The combination therapeutic regimen of radiotherapy with other therapeutic methods, including chemotherapy and immunotherapy, has been applied in clinical practice. Meanwhile, radiation toxicity and radiosensitivity have long been problems that affect a patient’s quality of life and morbidity. Researchers have found that the abovementioned problems are closely associated with gut microbiota. Here we discuss the impact of immune response induced by radiotherapy on tumor regression and the impact of intestinal flora on the consequent clinical efficacy.Keywords
This publication has 51 references indexed in Scilit:
- Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?Science, 2013
- Intestinal Inflammation Targets Cancer-Inducing Activity of the MicrobiotaScience, 2012
- Human Intestinal Lumen and Mucosa-Associated Microbiota in Patients with Colorectal CancerPLOS ONE, 2012
- Fusobacterium nucleatum infection is prevalent in human colorectal carcinomaGenome Research, 2011
- Autocrine TGF-β and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblastsProceedings of the National Academy of Sciences, 2010
- Adjuvant Therapy With Agonistic Antibodies to CD134 (OX40) Increases Local Control After Surgical or Radiation Therapy of Cancer in MiceJournal of Immunotherapy, 2010
- MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18Journal of Experimental Medicine, 2010
- Control of Immunity by the TNFR-Related Molecule OX40 (CD134)Annual Review of Immunology, 2010
- Tumor microenvironment: The role of the tumor stroma in cancerJournal of Cellular Biochemistry, 2007
- Fibroblasts in cancerNature Reviews Cancer, 2006